Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 184INDUSTRY 61NIH 33NETWORK 9OTHER_GOV 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2

Conditions

Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1

Interventions

Cisplatin 48Capecitabine 41Gemcitabine 33apatinib 32Oxaliplatin 32Cyclophosphamide 31Radiotherapy 29Paclitaxel 29Carboplatin 29tislelizumab 27Irinotecan 27Drug Therapy 27Fluorouracil 26Docetaxel 26Bevacizumab 23fludarabine 18Nivolumab 17pembrolizumab 16Surgical Procedures, Operative 16Exercise 16Metformin 15S 1 (combination) 14camrelizumab 13Radiation 13Pemetrexed 13Control Groups 12anlotinib 11Leucovorin 11Vinorelbine 10Standard of Care 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER_GOV × Interventional × Dasatinib × Clear all
NCT03414450 2018-10-25

Evaluation of ETC-1907206 With Dasatinib in Advanced Haematologic Malignancies

EDDC (Experimental Drug Development Centre), A*STAR Research Entities

Phase 1 Withdrawn
Other hematologic neoplasm

Leukemia, Myeloid, Accelerated Phase

NCT02113319 2014-04-14

DasaCBF

University Hospital, Angers

Phase 2 Completed
27 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡